【4565】そーせいG 441 【新年度入り：2018年度から12月期決算へ移行】
■ このスレッドは過去ログ倉庫に格納されています
で今期残りで結局何の契約も出なかったのかな？
皆んな心配してたがそうなったのか 5月は2017/3月期の通期決算
12月は2018/12月期の通期決算(4月～12月分だけ)ってことでええの？ そろそろ外人の売り攻勢も反転しそうだけどどちらにせよ高値は12000だろう
五味さんの出口戦略はどうするつもりなのかな 「今年はバイオ来ます！1万5千を通過点に、2万以上はッッ！」って、去年言ったＯ三証券から
電話が来ません（；＾ω＾） 今年の流行語大賞
これからはゲノム編集が一般的になれば、創薬ベンチャーなんでゴミ以下。 ここやサイバーダインやパークシャやサンバイオがだいたい時価総額１５００～２０００億くらい
ミクシィが３Qまでの最終利益２５０億くらいで時価総額３０００億くらい
今のところマザーズは思惑や将来性では２０００億くらいまでで実績上げても３０００億くらいまでの評価
それぞれ個別の事情はあるにせよ今のマザーズは時価総額上がると渋いねぇ 本スレにピーターは腕組んでるし、にやけてるし、禿げてないからダメだって書いてあった
あの経営者に期待してはいけないみたいだ そーせい売って仮想通貨買えって言ってたイモ元気か？
ビットコイン69万円だぞ？
ネム21円ｗｗｗ これで良いのか？
今まで
2017年04月～2018年03月（2018年3月期決算）・・・①
新改
2018年01月～2018年12月（2018年12月期決算）・・・②
2018年01月・02月・03月の3ヶ月が重複だがこの時期に
大きいＩＲはなし。
2018年05月に2018年3月期本決算発表（①）
同時に2018年（②）の第一四半期決算が発表
という事はもう第一四半期は終了して今日から第二四半期に突入か？ 重複するとか決算書読めない初心者か？
次は9ヶ月間でしめるんだよ。 9000円という南北境界線を超えてはいけないようだ あの連投奴、自分の連投だけじゃなくて別アカでも書き込んでるんじゃないの？ｗ 糞ゴミ株にも程があんな
何年も前からそーせい握ってる奴って精神的に異常だろ？
ストレス溜まって死ねる 淫売と知恵遅れのアイノコ、落ちてる菓子なんか拾ってる場合かｗｗｗ ところでバイオ全面高でここはマイナス取引ですがなぜですか？ そーせいだけでなく、１４時３０分頃から日経もマイテンした
なんか悪いニュースがあったの？ 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
Heptares and Imperial College seeking to rapidly advance drug discovery and translational research focused on multiple new and existing GPCR disease target.
Heptares Zurich: For our branch in Schlieren, we are looking for an enthusiastic and motivated personality by the middle of 2018 as biology lab technician (70-100%).
MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub on Imperial College London Campus.
・・・
※Heptares: We are seeking a"One Year Fixed Term Medicinal/Synthetic Industrial Post-Doctoral Position (Research Scientist)". (2/28 Closed)
※Heptares: We are recruiting for a "One-Year Fixed Term Medicinal / Synthetic Chemist (Scientist)". (2/28 Closed)
※Heptares: We are recruiting for a "Cryo-Electron Microscopy Scientist" to join our biophysics group. (3/13 Closed)
※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". (3/14Closed)
※Heptares: We are seeking a skilled "Computational Chemist" to Join the computational chemist team GPCR. (3/15 Closed)
※Heptares: We are growing our established Medicinal Chemistry Team and are seeking Scientist with Synthetic Organic Chemistry; One-Year Fixed Term Position. (4/3Closing→3/24Closed)
・・・
※Heptares: We are currently seeking a highly motivated and skilled organic chemist to join the "Medicinal Chemistry Team as a Research Scientist; Post-Doctoral, One-Year Fixed Term Position". (4/3 Closing)
※Heptares: We are now seeking to recruit a highly motivated "Analytical / Separation Scientist (Scientist/Research Scientist Grade)" GPCR. (4/3 Closing)
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. (4/17 Closing)
※Imperial College London: We are seeking a Post-Doctoral Scientist "Research Associate" with a background in engineering or physical sciences. Heptares Partnership Project. (4/17 Closing)
※Heptares: We are now seeking to recruit an experienced Protein Biochemist for a One-Year Fixed term contract. (4/18 Closing)
※Heptares: By mid-2018, we are seeking for our site in Schlieren/Zurich (Switzerland) an enthusiastic and motivated "Laboratory Technician (70-100%)". (4/20 Closing)
※Heptares: We are currently seeking an experienced Molecular Biologist to join the protein engineering group working on GPCR structure determination to enable drug discovery efforts. (4/29Closing)
・・・ ※SOSEIの成長相場の動向：
2010/12/30 (終値_1350) ・(2010/10/15※最安値_650、2010/12/27最高値_1748)
2011/12/30 (終値_1271) ・(2011/3/15※最安値__693、2011/6/30最高値_1680)
2012/12/28 (終値_2087) ・(2012/6/6※最安値__950、2012/9/7最高値_2967)
2013/12/30 (終値_4315) ・(2013/1/4※最安値_2050、2013/5/7最高値_6100)
2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ]
2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ]
2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ]
2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場]
2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ]
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移]
2018/_3/23 (終値_8590) 売残高14100 買残高 2046500(+26600) ・(3/5安値_8780) (3/23安値_8580) (3/26最安値_8320)※[悪地合いにて再びの拾い場]
2018/_3/30 (終値_8820) 5日線乖離(+1.38%) 25日線乖離(-4.20％) 75日線乖離(-14.76％) 200日線乖離(-15.91％) (安値_8620)
2018/_4/_2 (終値_8810) 5日線乖離(+0.80%) 25日線乖離(-3.97％) 75日線乖離(-14.72％) 200日線乖離(-15.91％) (安値_8770)
ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=9999&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整は順調に推移。笑。
時間軸調整終盤、予定通りに推移、今回も面白くなりましたね。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 俺も23,400株から200株まで減らして今400株で気楽やわｗ
レビー始動したら1,000株まで増やそうかな ※School of Life Sciences at Fudan University: Lu Boxun's Research Team and Collaborators Jointly Discovered Small Molecule Drug Candidates for the Treatment of Huntington's Disease. (3/28)
※Shanghai Institute of Chinese Academy of Sciences: Fudan University cooperates with Shanghai Institute to discover small molecule drug candidates for treating Huntington's disease. (3/30)
↓
※Chinese Academy of Sciences: Shanghai Drug Institute finds small molecule drug candidates for the treatment of Huntington's disease. (4/2up)
・The study found that it has applied for patents for inventions, It has also attracted the attention of Hepcares, an international pharmaceutical company, and entered into the signing of a cooperation agreement.
http://www.cas.cn/syky/201803/t20180330_4640463.shtml
※Sunovion: Utibron and Seebri, Savings Card (Savings Program: Valid for up to $250 off; cost may be as little as a $0 Co-Pay; qualify for a 30-Day Trial Offer): Expiration: 2018/3/31→"2019/3/31". (4/1update )
Heptares Event update (4/1up)
※2018 Workshop on Free Energy Methods, Kinetics and Markov State Models in Drug Design: Cambridge, MA, May 14 -18, 2018.
・Posters Announcing: "Metadynamics with Desmond and SuMTD to predict drug-GPCR kinetics.": Giovanni Bottegoni, Heptares. ※Allergan : to Report First Quarter 2018 Earnings and Host Conference Call and Webcast. (4/2up)
DUBLIN, April 2, 2018 -- Allergan plc today announced it intends to release first quarter 2018 financial results on Monday, April 30, 2018, prior to the open of U.S. financial markets.
Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Monday, April 30, 2018 to discuss its financial results.
↓
Results Event update
※Novartis First Quarter Results 2018: (4/19)
※第一三共2018年3月期決算発表: (4/27)
※Allergan Q1 2018 Earnings Release: (4/30)
※Pfizer Q1 2018 Earnings Release: (5/1)
※MorphoSys Q1 2018 Earnings Release. (5/3)
※あすか製薬 平成30年3月期決算発表: (5月上旬)
※Pluristem Q3 2018 Earnings Release: (5/ )
※大日本住友製薬 2018年3月期決算発表: (5/11)
※明治ホールディングス 平成30年3月期決算発表: (5/11)
※SOSEI 平成30年3月期決算発表: (5月中旬)
※ペプチドリーム 平成30年6月期第3四半期決算発表: (5/16予定)
※AstraZeneca Q1 2018 Earnings Release: (5/18)
・・・ 明日の日経は下がる
下がる時だけ一緒
氏ね糞ゴミ株 地合いがー地合いがー
ダウ-2%
日経-4%
そーせい-10%
wwwww >>95
最近あげてたから反動は大きいやろうな
マイナス10パーセントで済めば実質勝ちだろうな 米通商製造政策局長、米中の報復の連鎖想定せず 中国の対応受け
なんかきたああああああああああああああああああああああああああああああああああああああああああああああああああああああ ファイザーに導出って絶望的なの？
一発1万円の風俗とは訳が違うぞ
一発200億円とかじゃなかったっけ？
なぜこれほど株価は低いんだ？ >>99
お前が売ったらすぐIR出るから売ったほうがいいよ >>99
これだけ時間が経っても何もないということは
わかるよな
察しろよ 大村紙業が後場ストップ高、ニンテンドースイッチに関与の思惑再燃
http://kabuguide.net/rsslist/japanese-stocks/100752
大村紙業(3953)がストップ高、「ニンテンドーラボ」発売接近で再度連想買い
https://marketpress.jp/company/44710/
大相場の初動 目標株価4000円 目標株価とか言う絵に描いた餅ならそーせいも負けてないぞ 下げには率先して反応しますね...
相当な不人気株です >>104
素晴らしいね
この空売りの安心感
下だけに反応するからやりやすい 結局GPCRって使えない偽物だったって事だよ。スタップ細胞と同じ。 社長が自分の株売り抜けるために、総会で大ボラ吹いて吊り上げて、自分だけ売り抜けして、社長辞めてドロンしてる、会社の株世界中のまともな投資家相手するわけないやん。みんなよく考えろ。 ぺプチはプラ点、そーせいさんは・・・・・・。
この違いについて述べよ >>109
幼稚な株価と言って高値で売り抜け
あれには山師さん＠トレード中もびっくり >>110
信用の違い
そーせいは信用がない
偽物だから ブラックロック売り増し！！！
これは本気絶対下がるぞ
3桁目指すわ 赤字企業だし将来性もなさそうだし二桁もあり得るよね？ 五味の取得単価12012円28％も含み損
絶望的じゃねえかｗ >>124
第一筆頭株主の取得単価12012円28％も含み損って >>122
余裕で2桁なると思う
問題は時期やね
下値余地大きすぎるから空売り絶対有利なんだけど
個人も無期限空売りさせろやな！ >>124
それデマじゃないの？
そもそも五味さん、かなりそーせいで利確してるだろｗ 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares is Currently Based in Welwyn Garden City but will be Moving to a brand New Research Facility at Granta Park (Cambridge) in July 2018.
Heptares has been Operating Approximately 130 Employees who will all be based in this New Research Facility.
Heptares and Imperial College seeking to rapidly advance drug discovery and translational research focused on multiple new and existing GPCR disease target.
Heptares Zurich: For our branch in Schlieren, we are looking for an enthusiastic and motivated personality by the middle of 2018 as biology lab technician (70-100%).
Pluristem is working hard to negotiate the best possible terms for a Japanese JV and will provide an update upon reaching an agreement.
MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub on Imperial College London Campus.
Novartis: Ultibro New Version of the Breezhaler Device (Concept2: Digital Adherence System). The First Clinical Study with this Inhaler is due to begin this Year.
Vectura: Ultibro and Seebri, 2017 combined net sales of $562 million, £17.3 million of Royalties. "In our 2018 outlook strong growth of revenues driven by Ultibro."
ペプチドリーム：Heptares戦略的提携、この共同研究では、両社のもつ業界屈指のプラットフォーム技術を集結。両社での取組みは着実に進んでおり、近く進捗状況の報告が提供できる。
JITSUBO：インドNeulandとの包括的パートナーシップに向けた覚書締結。日本の先端技術とインドの高い製造能力・豊富な実績の国際連携で、大きなシナジーを創出。
SOSEI：片頭痛、その他重度の頭痛に対する治療薬である新規低分子CGRP拮抗薬のグローバルにおける開発・販売の権利をTeva社が返還。臨床開発の段階へ迅速に進められる状態。
四季報：自社パイプライン：他社との提携・導出に加え、自社販売視野に入れた開発候補７品目保有。18年内にレビー小体型認知症薬は2相、神経性疾患薬は1相入り目指す。
SOSEI個人投資家説明会(動画)：ピーター・ベインズ挨拶、HTL001831の開発(日本)、研究開発パイプライン。http://www.sosei.com/ir/library/results_briefing.html
・・・ ※SOSEIの成長相場の動向：
2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ]
2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ]
2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ]
2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場]
2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ]
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(2017/12/6安値_9970)※[振るいも順調に推移]
2018/_3/30 (終値_8820) 売残高14400 買残高 2028000(-18500)※4/3up ・(3/26最安値_8320)※[悪地合いにて再びの拾い場]
2018/_4/_2 (終値_8810) 5日線乖離(+0.80%) 25日線乖離(-3.97％) 75日線乖離(-14.72％) 200日線乖離(-15.91％) (安値_8770)
2018/_4/_3 (終値_8750) 5日線乖離(+0.46%) 25日線乖離(-4.21％) 75日線乖離(-15.13％) 200日線乖離(-16.39％) (安値_8550)
更なる成長の黎明期、上抜け圏にて、強気相場解除後の時間軸での調整は順調に推移。笑。
時間軸調整終盤、予定通りに推移、今回も面白くなりましたね。笑。
成長戦略の進捗と共に、次なる展開・進捗が楽しみです。笑。 >>128
大量保有報告書に記載されているから事実
https://disclosure.edinet-fsa.go.jp/E01EW/download?
uji.verb=W0EZA104CXP001003Action&uji.bean=ee.bean.parent.EECommonSearch
Bean&PID=W1E63011&SESSIONKEY=1522741448335&lgKbn=2&pkbn=0&skbn=
1&dskb=&askb=&dflg=0&iflg=0&preId=1&mul=%E3%81%9D%E3%83%BC%E3%81%9B%E3%81%84&lpr=
on&cal=1&era=H&yer=&mon=&pfs=4&row=100&idx=0&str=&kbn=1&flg=&syoruiKanriNo=&s=S100BE2M >>131
仮に今現在の取得単価が五ケタでも利確してるんだろうし現物だし問題無いでしょ？
糞貧乏人に心配されてる五味さんも色々大変だなｗ ※Heptares Therapeutics Zurich Limited - Schlieren: "Group Leader Protein Biochemistry - Heptares Zurich". (4/3up)
Heptares is a Drug Discovery Company working on G protein-coupled receptors (GPCRs) involved in CNS and metabolic diseases.
Our unique structure-based approach in discovering therapeutic agents for these diseases relies on a proprietary technology to stabilize GPCRs,
enabling their purification for structural and biophysical studies.
The company works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes;
and is also developing its own pipeline of proprietary molecules.
The most advanced of these are now in clinical studies with others moving towards clinical development.
We are currently seeking an experienced protein biochemist to grow and lead our newly established protein biochemistry group
at our site in Zurich working towards GPCR structure determination to enable drug discovery efforts.
"Group Leader Protein Biochemistry Heptares Zurich"
Our preferred candidate will have the following profile:
・PhD in biochemistry or related discipline
・Proven ability to grow, teach and lead a team (PhD level and technician)
・Experienced in molecular biology
・Experienced in membrane protein expression methods in mammalian and insect cells
・Experienced in membrane protein purification using AEKTA Pure systems
・Excellent knowledge of protein QC and troubleshooting
・Experienced in preparation of protein for membrane protein crystallization (lipidic cubic phase and vapor diffusion)
・Experience in setting up crystallization using automated systems would be an advantage
・Ability to work flexibly within a team whilst being highly self-motivated and work independently
・Analytical thinking and good problem-solving skills
・Excellent organizational and time management skills as well as the ability to work to strict deadlines
・Experienced in hands-on teaching and training of junior staff
・Fluency in oral and written English; a knowledge of German is preferred The successful candidate will be expected to work independently and manage staff, and the role will include the following responsibilities:
・Lead and line manage staff of the protein biochemistry group (initial hands-on experience is required)
・Grow the team from currently 2 FTEs to 5 FTEs by 2020
・Train and teach junior staff and set individual and group objectives
・Close interaction with protein biochemistry group in the UK
・Coordinate requirements with HZ Management
・Coordination of work and QC to guarantee transfer of protein for crystallization
・Careful documentation of experimental work; and,
・Work closely with molecular biologists, protein expression scientists, crystallographers and pharmacologists to help advance the multidisciplinary drug development projects
・Develop and optimize local protein QC capabilities – establish local opportunities
Groups responsibilities are:
・Characterization of GPCRs expression in membrane and in solubilized form
・Coordination of material requirements between expression and purification
・Construct engineering to optimize GPCRs for crystallization
・Purification of GPCRs and biochemical characterization using a range of analytical techniques such as size exclusion chromatography - develop and optimize processes
・Progression of purified material into crystallization
This is an exceptional opportunity to participate in growing and shaping our site new site in Zurich.
The closing date for applications is 5th of May 2018. ※Heptares Therapeutics Zurich Limited - Schlieren: "Junior Protein Biochemist – Heptares Zurich". (4/3up)
Company Description:
Heptares is a Drug Discovery Company working on G protein-coupled receptors (GPCRs) involved in CNS and metabolic diseases.
Our unique structure-based approach in discovering therapeutic agents for these diseases relies on a proprietary technology to stabilize GPCRs, enabling their purification for structural and biophysical studies.
The company works in collaboration with major global pharmaceutical companies on both small molecule and antibody discovery programmes; and is also developing its own pipeline of proprietary molecules.
The most advanced of these are now in clinical studies with others moving towards clinical development.
Position
We are currently seeking an experienced protein biochemist to join our site in Zurich working towards GPCR structure determination to enable drug discovery efforts.
The successful candidate will be expected to work independently as a member of our newly established protein biochemistry group, and the role will include the following responsibilities:
・Cloning of plasmid constructs for expression of crystallization constructs;
・Expression of GPCRs in insect and mammalian cells;
・Characterization of GPCRs expression in membrane and in solubilized form;
・Construct engineering to optimize GPCRs for crystallization;
・Purification of GPCRs and biochemical characterization using a range of analytical techniques such as size exclusion chromatography
・Careful documentation of experimental work; and,
・Work closely with the company’s project based interdisciplinary task-forces of molecular biologists, protein expression scientists, crystallographers and pharmacologists to help advance our drug development efforts.
Requirements:
Our preferred candidate will have the following profile:
・PhD in biochemistry or equivalent (3 years’ experience in membrane protein biochemistry)
・Experience in molecular biology
・Experience in membrane protein expression methods in mammalian and insect cells;
・Experience in membrane protein purification using AEKTA Pure systems;
・Experience in preparation of protein for membrane protein crystallization would be of advantage
・Ability to work flexibly within a team whilst being highly self-motivated and work independently;
・Analytical thinking and good problem solving skills;
・Excellent organizational and time management skills as well as the ability to work to strict deadlines;
・Fluency in oral and written English; a knowledge of German is preferred
Other information:
This is an exceptional opportunity to participate in pioneering science with an Industry-leading Drug Discovery company.
The closing date for applications is 5h of May 2018. >>133
糞貧乏人のお前に言われても説得力ねえよ 五味さんが抜けられるのは二万くらいでしばらく安定しないとならんからまだまだ数年先の話だわな Events update:
※CECAM Workshops: CompAllo: Towards a Unified Approach to the Analysis and Design of Allostery: Lausanne, Switzerland: April 9-11, 2018.
・Invited Speaker: Rob Cooke (Heptares).
※3rd North American SMALP Conference: Overcoming Bottlenecks in Membrane Biology: Alberta Canada, April 11, 2018.
・April 11, 14:10-14:30, "Structure-Based Drug Design of GPCRs": Jana Broecker (Heptares).
※UK-QSAR Group and Molecular Graphics and Modelling Society Joint Conference "Structure-Activity Relationships", University of Cardiff, UK: April 11-12, 2018.
・Apr 12, 14:30, "Beyond the Happy Water - recent advances in the quantification of contributions": Ben Tehan (Heptares).
※EASL(European Association for the Study of the Liver) International Liver Congress: Paris, France, 11-15 April 2018.
・MiNA Therapeutics.
※大阪大学蛋白質研究所：第2回感覚器研究イニシアチブ・シンポジウム：4月15日13：00、大阪大学吹田キャンパス/銀杏会館
・16:53-17:23 「幻視の発現機構」 森悦朗：大阪大学大学院連合小児発達学研究科行動神経学・神経精神医学寄附講座(Heptares寄附講座)教授
※Oxford Global Conferences, 5th Annual Peptides Congress: London, UK: April 16-17, 2018.
・Cedric Fiez-Vandal, Senior Scientist (Heptares).
※ASPET Annual Meeting at Experimental Biology 2018: San Diego, CA, USA, Apr 21-25, 2018.
・Apr 24, "X-Ray Structures of GPCRs Provide Insights into New Binding Sites for Drug Discovery": Jon Mason (Heptares).
※Annual Conference for the Advancement of Clinical Research in Israel: April 24, 2018.
・11:40, Zami Aberman, Chairman & Co-CEO, Pluristem. ※Basel Area, Swiss Life Sciences Event: "Between Basic Research and Biotech Entrepreneurship": Andreas Pluckthun (co-founder of Morphosys, Molecular Partners and G7 Therapeutics (now Heptares-Zurich)).
・Apr 24, 19:00-20:00, "Andreas Pluckthun": He recounts how he successfully co-founded several biotech companies and how the ecosystem for startups has evolved in the last 20 years.
※TIDES: Oligonucleotide and Peptide Therapeutics 2018: Boston, MA, USA, May 7-10, 2018.
・May 10, 10:45-11:15, mRNA, CRISPR and Hot Topics in Oligonucleotides: "RNA Activation in NASH, Liver Failure and Hepatocellular Carcinoma": Nagy Habib, MD Head of R&D, MiNA Therapeutics.
※World Advanced Therapies & Regenerative Medicine Congress: London, May 16 - 18 2018.
・May 17, 14:50, "Engineering cell therapeutics for controlled drug delivery - clinical case studies": Zami Aberman, Chairman and Chief Executive Officer, Pluristem.
※World Advanced Therapies & Regenerative Medicine Congress 2018, London: 16–18 May 2018
・May 17, 15:10 , "Placental derived cell for allogeneic treatment of solid cancer": Zami Aberman, Chairman and Chief Executive Officer, Pluristem.
※ASGCT 21st Annual Meeting: Chicago, IL, 16-19 May 2018.
・May 18, 9:00, "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC.": Nagy Habib (MiNA Therapeutics), Imperial College of London.
※ATS(American Thoracic Society) International Conference 2018: San Diego, CA USA, May 18-23 2018.
・May 21, 14:15, "Lung deflation and improvement of cardiac end-diastolic volumes with indacaterol/glycopyrronium reduce dyspnea and improve health status in hyperinflated COPD patients: the CLAIM study": Jens Hohlfeld.
※ASCO Annual Meeting: Chicago, IL, 1-5 June 2018.
・MiNA Therapeutics.
※The BIO International Convention 2018: Boston, MA, June 4-7, 2018.
・Yaky Yanay, President & Co-CEO, Pluristem. ※NovAlix Biophysics in Drug Discovery 2018: Boston, MA, USA, Jun 13-15, 2018
・June 14, 15:10, "Structural Insight into Allosteric Modulation of GPCRs": Dr Miles Congreve (Heptares)
※23rd Annual Congress of EHA (European Hematology Association): Stockholm, Sweden, 14-17 June 2018.
・MiNA Therapeutics.
※7th LSX CEO Forum (formerly Biotech and Money CEO Forum), London: 28 June 2018.
・14:15, Case Studies and Peer Review: "Sosei - AZ immune-oncology collaboration" - Malcolm Weir, Chief R&D officer, Sosei (former CEO Heptares) (Invited).
※Adrenoreceptors 2018, Receptor Structure Changes the Pharmacology Paradigm: Shizuoka, Japan, Jun 28-30, 2018
・Jun 28, "Structural insight driving commercial drug discovery": Rob Cooke (Heptares)
※18th World Congress of Basic and Clinical Pharmacology (WCP2018) Kyoto, Japan: July 1- 6, 2018.
・July 6, 10:20, "Biased apelin receptor agonists for cardiovascular disease" :Anthony P. Davenport, University of Cambridge, UK, (Heptares ORBIT Projects)
※日本核酸医薬学会 第４回年会, 博多, 日本：2018年7月9日～11日.
・MiNA Therapeutics.
※Early Career Scientist Forum on GPCR Signal Transduction (ECSF-GPCR): Berlin, Germany, Jul 11-14, 2018
・Ali Jazayeri (Heptares)
・・・
※7th SCI/RSC Symposium on GPCRs in Medicinal Chemistry, Verona, Italy: September 10-12, 2018.
・Sep 11, 9:30 "Keynote: Application of structure-based drug design to peptidergic GPCRs": Miles Congreve, Heptares Therapeutics.
・Sep 12, 9:00 "Keynote: Shedding light on G protein bias: structures of GPCRs coupled to G proteins determined by cryo-EM and X-ray crystallography": Chris Tate, MRC LMB.
・・・ 五味さん資産200億以上あるやろ
お前ら人の買い単価調べる暇あったら自分の心配しろよw ごみさん、ツイッターで、今年に入ってコツコツ売ってますみたいな書き込みあったやん
つまり、今の売り本尊はゴミさんでしょ
一回ストップ安おこして、株数増やそうとしてるはず 今年に入ってってもう3ヶ月もコツコツ売り続けてたら変更報告書出してないとおかしいやろ gcnはごみだいすけだとおもうけど、すぐ消すからいちいち読んでな。売ってるっていってたの？ どう見ても有望な自社開発、自社販売用のパイプラインを有していることを、もっと評価すべきだと思うのですが。
まあ、その時が来たら、「あの時買っていれば今頃は…」なんていうことになるんですけどね。 ■ このスレッドは過去ログ倉庫に格納されています
